Insider Selling: Scholar Rock (NASDAQ:SRRK) Insider Sells 20,438 Shares of Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) insider Akshay Vaishnaw sold 20,438 shares of the business’s stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $42.70, for a total transaction of $872,702.60. Following the transaction, the insider owned 595,767 shares of the company’s stock, valued at approximately $25,439,250.90. This trade represents a 3.32% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Scholar Rock Stock Up 2.1%

SRRK traded up $0.95 during trading on Thursday, hitting $46.53. The stock had a trading volume of 988,383 shares, compared to its average volume of 911,044. The stock has a 50 day simple moving average of $42.02 and a two-hundred day simple moving average of $36.87. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.30 and a current ratio of 6.30. Scholar Rock Holding Corporation has a twelve month low of $22.71 and a twelve month high of $48.28. The company has a market capitalization of $4.75 billion, a PE ratio of -14.77 and a beta of 0.63.

Scholar Rock (NASDAQ:SRRK) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.02). During the same quarter in the previous year, the firm posted ($0.66) earnings per share. On average, research analysts predict that Scholar Rock Holding Corporation will post -2.42 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. Moody Aldrich Partners LLC increased its stake in shares of Scholar Rock by 53.5% in the 3rd quarter. Moody Aldrich Partners LLC now owns 101,742 shares of the company’s stock valued at $3,789,000 after purchasing an additional 35,481 shares in the last quarter. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. grew its holdings in Scholar Rock by 145.3% in the second quarter. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. now owns 769,442 shares of the company’s stock valued at $27,254,000 after purchasing an additional 455,753 shares during the period. Norges Bank purchased a new stake in shares of Scholar Rock in the second quarter valued at approximately $41,628,000. Voya Investment Management LLC increased its position in shares of Scholar Rock by 18.1% in the third quarter. Voya Investment Management LLC now owns 443,155 shares of the company’s stock valued at $16,503,000 after buying an additional 67,839 shares in the last quarter. Finally, Intech Investment Management LLC raised its stake in shares of Scholar Rock by 60.9% during the 1st quarter. Intech Investment Management LLC now owns 56,784 shares of the company’s stock worth $1,826,000 after buying an additional 21,483 shares during the period. Hedge funds and other institutional investors own 91.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on SRRK shares. Truist Financial dropped their price target on Scholar Rock from $54.00 to $44.00 and set a “buy” rating on the stock in a research note on Monday, October 20th. Wolfe Research assumed coverage on shares of Scholar Rock in a research note on Tuesday, November 18th. They set an “outperform” rating and a $42.00 price target on the stock. Piper Sandler decreased their price target on shares of Scholar Rock from $52.00 to $51.00 and set an “overweight” rating for the company in a report on Wednesday, September 24th. Cantor Fitzgerald reissued an “overweight” rating on shares of Scholar Rock in a report on Thursday, December 11th. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $50.00 target price on shares of Scholar Rock in a research report on Friday, November 14th. Four research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $50.14.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).